Let the sun shine in: Mechanisms and potential for therapeutics in skin photodamage

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Photoaging and photocarcinogenesis are the two Janus faces of skin photodamage. Reactivity-based design of prototype agents that antagonize, modulate and reverse the chemistry of skin photodamage holds promise in delivering unprecedented therapeutic benefit. In contrast to structure-based approaches that use selective ligands to target macromolecules, reactivity-based drug discovery uses chemical reagents as therapeutics to target reactive chemical species as key mediators of skin photo-oxidative stress. The following classes of reactivity-based agents for skin photoprotection can be distinguished based on their mechanism of action: direct antagonists of photo-oxidative stress (sunscreens, quenchers of photo-excited states, antioxidants, redox modulators and glycation inhibitors) and skin photo-adaptation inducers (nuclear factor erythroid 2-related factor 2 [Nrf2] activators, heat-shock response inducers and metallothionein inducers).

Original languageEnglish (US)
Pages (from-to)390-400
Number of pages11
JournalCurrent Opinion in Investigational Drugs
Volume8
Issue number5
StatePublished - May 2007

Fingerprint

Solar System
Skin
Oxidative Stress
Therapeutics
Heat-Shock Response
Sunscreening Agents
Metallothionein
Drug Discovery
Oxidation-Reduction
Antioxidants
Ligands

Keywords

  • Antioxidant
  • Carbonyl scavenger
  • Glycation inhibitor
  • Heat-shock response inducer
  • Metal chelator
  • Photo-oxidative stress
  • Photoaging
  • Photodamage
  • Photoprotection
  • Skin photo-adaptation inducer

ASJC Scopus subject areas

  • Pharmacology

Cite this

Let the sun shine in : Mechanisms and potential for therapeutics in skin photodamage. / Wondrak, Georg T.

In: Current Opinion in Investigational Drugs, Vol. 8, No. 5, 05.2007, p. 390-400.

Research output: Contribution to journalArticle

@article{94fc1b9c91c6408ca9b9ce753ed8ddc8,
title = "Let the sun shine in: Mechanisms and potential for therapeutics in skin photodamage",
abstract = "Photoaging and photocarcinogenesis are the two Janus faces of skin photodamage. Reactivity-based design of prototype agents that antagonize, modulate and reverse the chemistry of skin photodamage holds promise in delivering unprecedented therapeutic benefit. In contrast to structure-based approaches that use selective ligands to target macromolecules, reactivity-based drug discovery uses chemical reagents as therapeutics to target reactive chemical species as key mediators of skin photo-oxidative stress. The following classes of reactivity-based agents for skin photoprotection can be distinguished based on their mechanism of action: direct antagonists of photo-oxidative stress (sunscreens, quenchers of photo-excited states, antioxidants, redox modulators and glycation inhibitors) and skin photo-adaptation inducers (nuclear factor erythroid 2-related factor 2 [Nrf2] activators, heat-shock response inducers and metallothionein inducers).",
keywords = "Antioxidant, Carbonyl scavenger, Glycation inhibitor, Heat-shock response inducer, Metal chelator, Photo-oxidative stress, Photoaging, Photodamage, Photoprotection, Skin photo-adaptation inducer",
author = "Wondrak, {Georg T}",
year = "2007",
month = "5",
language = "English (US)",
volume = "8",
pages = "390--400",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Let the sun shine in

T2 - Mechanisms and potential for therapeutics in skin photodamage

AU - Wondrak, Georg T

PY - 2007/5

Y1 - 2007/5

N2 - Photoaging and photocarcinogenesis are the two Janus faces of skin photodamage. Reactivity-based design of prototype agents that antagonize, modulate and reverse the chemistry of skin photodamage holds promise in delivering unprecedented therapeutic benefit. In contrast to structure-based approaches that use selective ligands to target macromolecules, reactivity-based drug discovery uses chemical reagents as therapeutics to target reactive chemical species as key mediators of skin photo-oxidative stress. The following classes of reactivity-based agents for skin photoprotection can be distinguished based on their mechanism of action: direct antagonists of photo-oxidative stress (sunscreens, quenchers of photo-excited states, antioxidants, redox modulators and glycation inhibitors) and skin photo-adaptation inducers (nuclear factor erythroid 2-related factor 2 [Nrf2] activators, heat-shock response inducers and metallothionein inducers).

AB - Photoaging and photocarcinogenesis are the two Janus faces of skin photodamage. Reactivity-based design of prototype agents that antagonize, modulate and reverse the chemistry of skin photodamage holds promise in delivering unprecedented therapeutic benefit. In contrast to structure-based approaches that use selective ligands to target macromolecules, reactivity-based drug discovery uses chemical reagents as therapeutics to target reactive chemical species as key mediators of skin photo-oxidative stress. The following classes of reactivity-based agents for skin photoprotection can be distinguished based on their mechanism of action: direct antagonists of photo-oxidative stress (sunscreens, quenchers of photo-excited states, antioxidants, redox modulators and glycation inhibitors) and skin photo-adaptation inducers (nuclear factor erythroid 2-related factor 2 [Nrf2] activators, heat-shock response inducers and metallothionein inducers).

KW - Antioxidant

KW - Carbonyl scavenger

KW - Glycation inhibitor

KW - Heat-shock response inducer

KW - Metal chelator

KW - Photo-oxidative stress

KW - Photoaging

KW - Photodamage

KW - Photoprotection

KW - Skin photo-adaptation inducer

UR - http://www.scopus.com/inward/record.url?scp=34247846134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247846134&partnerID=8YFLogxK

M3 - Article

C2 - 17520868

AN - SCOPUS:34247846134

VL - 8

SP - 390

EP - 400

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 5

ER -